UAE-based pharmaceutical manufacturer Globalpharma has signed seven Memorandums of Understanding (MoUs) aimed at strengthening research and development, manufacturing capabilities, operational efficiency and sustainable growth across its operations.
The agreements are structured around three areas: innovation and product development; manufacturing, efficiency and sustainability; and market access, financing and expansion. The partnerships include collaboration with ZIM Laboratories FZE and Molkem Chemicals Pvt. Ltd.; Masibus (a Sonepar company), Rockwell Automation and 386 Sky Solar Energy Systems LLC; as well as Emirates Development Bank (EDB), Mubadala Bio’s Al Ittihad Drug Store (IDS) and the Emirates Drug Establishment (EDE).
For manufacturing-focused sectors, the initiative highlights increased investment in automation, digitalisation and operational optimisation. Globalpharma said its collaboration with Masibus and Rockwell Automation is intended to support advanced automation technologies to improve throughput, quality and real-time manufacturing visibility.
Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma, said: “These MoUs reflect a structured effort to enhance local capabilities, enable technology and knowledge transfer and support the development of a more resilient and competitive pharmaceutical manufacturing base in the UAE.”
The sustainability component includes deployment of a 612 kWp rooftop solar PV installation at the company’s Dubai Investment Park facility as part of broader operational efficiency efforts.